- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, including longer and shorter regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care.
Keywords: TB, HIV, drug-resistant, treatment, support and care
Concerted and integrated efforts are needed to prevent and address both TB and TB-HIV burden in the region.
2 out of 3 TB infections globally are in Asia and the Pacific and 60% of MDR-TB burden is in this region. Globally, Asia and the Pacific is the home for 13% of PLHIV but 20% of TB-HIV co-infections are in this region. Systematic collaboration between TB-HIV programmes will save lives and improve the quality of life of people living with and affected by HIV and TB.
The Compendium has been developed as a clear and concise instrument to facilitate the understanding and planning of delivery of high-quality care for everybody affected by TB. It incorporates all recent policy guidance from WHO; follows the care pathway of persons with signs or symptoms of TB in seeking diagnosis, treatment and care; and includes key algorithms and cross-cutting elements that are essential to a patient-centered approach in the cascade of TB care.
The WHO South-East Asia (SEA) Region has some of the highest TB-burden countries, and nearly half of all TB cases in the world are to be found in people from this Region. The Region has nearly half the global burden in terms of new cases (incidence), and close to 40% of the burden in terms of deaths due to TB. And this while only 26% of the global population lives in the Region.
Keywords: TB, drug-resistant, treatment, funding
WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This is done in the context of recommended global TB strategies and targets endorsed by WHO’s Member States and broader development goals set by the United Nations.
Keywords: TB, prevention, diagnosis, treatment, drug-resistant
HIV-associated TB presents a risk to achieving the Sustainable Development Goals. Effective, sustained action is required to meet the needs of the most vulnerable populations.
Keywords: TB, PLHIV, treatment, diagnostic, deaths
The 2018 United Nations General Assembly High-Level Meeting (HLM) on Tuberculosis and the current revision of the Roadmap for childhood tuberculosis together present an important moment to consolidate and advance advocacy, commitment, resource mobilization and joint efforts by all stakeholders to provide health care and address the burden of TB among children
Keywords: TB, HIV, multidrug-resistant, treatment, advocacy
This document captures the achievements from 2015-2017 of the Multi-Country Western Pacific Integrated HIV/TB Programme. The programme improved the coverage and quality of HIV/TB prevention, treatment and care in 11 countries: Cook Islands, Federated States of Micronesia, Kiribati, Marshall Islands, Nauru, Niue, Palau, Samoa, Tonga, Tuvalu and Vanuatu.
The 2018 United Nations General Assembly High-Level Meeting (HLM) on Tuberculosis and the current revision of the Roadmap for childhood tuberculosis together present an important moment to consolidate and advance advocacy, commitment, resource mobilization and joint efforts by all stakeholders to provide health care and address the burden of TB among children.
This document compiles examples of best practices at global, regional and country levels since the launch of the first edition of the Roadmap. It describes 36 examples from 24 countries (including 10 TB, two multidrug-resistant TB (MDR-TB) and four TB/ human immunodeficiency virus (HIV) high burden countries) from all the six WHO regions, two regional initiatives and 12 global initiatives. The examples are categorized according to the ten key actions from the 2013 Roadmap.